The global surgical robots market is projected to reach USD 23.7 billion by 2029, implying a CAGR of 16.5%. Using Next Generation Sequencing (NGS) and integrated analytics software, the company analyzes patient DNA to generate detailed pharmacogenomic reports for clinicians to prescribe the right medication at the right dose. A recent research highlights how genomics, transcriptomics, and multi-omics layered within precision medicine enable more accurate disease prediction, personalized interventions, and improved clinical outcomes.

According to a study published in Medical Economics, RPM interventions led to a 50% reduction in 30-day hospital readmissions for heart-failure patients. However, this maturity curve is steepening as governments and corporations recognize virtual care’s long-term value. Corporate telehealth networks are scaling cross-border, as seen with Hims & Hers’ acquisition of UK-based ZAVA in 2025.

Investment: 92% of Pharma Leaders Prioritise Precision Medicine

The inefficiencies caused by this disjointed process can impact a clinician’s ability to deliver timely diagnoses and treatments to patients. Meanwhile, adopting circular practices, which emphasize using less, using longer, and using again, is another way that both healthcare organizations and their suppliers are significantly reducing raw material usage and waste. Both refurbished consumer products and refurbished medical devices, including image-guided therapy systems and MRI scanners, offer sustainable and cost-efficient alternatives without compromising performance. The refurbished medical devices market is expected to grow from $17.05 billion in 2024 to $30.78 billion by 2029 10. By embracing collaborative efforts, healthcare organizations can significantly reduce their environmental impact.

Green procurement transforming the healthcare supply landscape

Australian startup Gene S provides a pharmacogenomics (PGx) platform that personalizes medication selection and dosing through advanced genetic testing. A 2025 review notes that integrating genomics with multi-omics and AI https://themors.com/where-europes-startups-are-thriving-in-2025/ for precision medicine is becoming a mainstream investment focus. Moreover, in oncology and precision therapeutics, investment in gene editing and genetic profile-based treatments is accelerating.

Predictive Analytics for Hospital Operations

By distributing AI and empowering employees with autonomy, businesses can achieve exponential innovation and growth. It’s about trusting people to lead the transformation, encouraging them to become automators and explore new ideas independently. Far beyond optimizing workflows, this approach liberates human potential with AI and fosters a culture where every employee is part of the engine for innovation and growth. Envision a future where every customer interaction is guided by a familiar face—a personified chatbot that embodies a beloved mascot or an influencer’s persona. This agent operates on the company’s channels or can join conversations on other AI platforms. Over time, it gets to know customers individually, building trust by taking relevant actions and leveraging digital tools to meet their needs exactly on their terms.

Consumers can’t stay away from convenience stores, data shows

With limited staff, many hospitals “delegate” routine tasks like patient follow-ups and appointment scheduling to Gen AI agents, trained to provide personalized answers based on the patient’s medical history. Further, the TechPain Device integrates with the TechPain Monitor and TechPain Web to provide healthcare professionals with real-time insights into pain intensity, frequency, and response to therapy. Its 3D printing technology integrates medical imaging data with additive manufacturing. This combination creates patient-specific models that replicate the softness, density, and mechanical behavior of biological structures. On the medical-device side, the global 3D printing-medical devices market is projected to reach USD 6.9 billion by 2028, implying a CAGR of 17.1% in that period.

• In oncology, AI models have successfully matched patients with effective therapies based on tumor genetics.
• AI is also being combined with other technologies to create smarter systems in healthcare, finance, and education.
• A systematic mapping study found that among 365 reviewed papers on mHealth/ubiquitous health systems, data governance and privacy validation remained underrepresented, which is impeding full-scale deployment.
• Academics and companies alike are developing agents that can carry out research tasks autonomously and work with scientists as genuine collaborators.
• Such transactions reflect a growing preference for diverse structures that allow existing owners to preserve meaningful participation while leveraging operators and management company administrative expertise.

This integration allows interventional physicians to treat patients with greater control and confidence during every stage of minimally invasive cardiac procedures. Generative AI has emerged as a powerful tool supporting this healthcare technology trend, promising to boost clinician productivity in ways that seemed impossible just a few years ago. It’s no wonder that 85% of healthcare leaders worldwide are already investing or plan to invest in generative AI within the next three years. We expect this trend to accelerate in 2025 as the sector continues to explore ways of gaining workflow efficiencies with generative AI. The rise of 5G and early development of 6G technology is also transforming communication networks. With faster speeds and lower latency, these networks are enabling innovations such as autonomous vehicles, remote surgeries, and immersive virtual experiences.

In the future, AI will offer increasingly personalized recommendations by comparing the full patient picture with thousands of similar cases to help determine the best approach for each patient. The latest innovations in image-guided therapy also offer a unique opportunity to expand access to life-saving stroke care. Every two seconds, someone on Earth has a stroke, making it the second leading cause of death and a major cause of long-term disability. Yet less than 5% of our global population has access to mechanical thrombectomy, a minimally invasive treatment that has shown to be highly effective 2. Expanding access by increasing the number of stroke-ready hospitals and training healthcare professionals in the latest interventional techniques is a cause that Philips is committed to, in partnership with the World Stroke Organization.

How can companies measure the ROI of investing in an emerging healthcare technology?

An analysis of more than 2.25 million IoMT devices across 351 healthcare organizations found that 99% of organizations had devices affected by known exploited vulnerabilities. In the US, the virtual-care market is projected to reach about USD 69.2 billion by 2034, with a CAGR of roughly 29.2%. At the same time, the telehealth services segment is projected to grow to USD 71.1 billion in 2025 and then to about USD 505.3 billion by 2034 at a CAGR of 24.3%. There is an acute lack of reimbursement due to investors’ concerns regarding the high cost of research and equipment, unclear pricing models and administrative procedures, a small number of patients, and a lack of comprehensive safety and efficiency data. The new devices and apps that comply with the high-end capabilities of 5G are poised to take the market by storm!

Also in this space, Heidi Health, Australia’s leading healthcare AI platform, acquired AutoMedica, a UK-based clinical AI startup focused on evidence-led frameworks and regulatory-compliant clinical reasoning. The acquisition strengthens Heidi’s capabilities beyond documentation into real-time evidence generation and patient communication tools while supporting its international expansion and UK/EU regulatory relationships. At the 44th Annual J.P. Morgan Healthcare Conference held in January 2026, Jeremy Meilman, global head of Healthcare Investment Banking at J.P. Q continued a pattern of strategic consolidation in the clinical research space, with acquirers targeting specialized therapeutic expertise and novel delivery models to differentiate their platforms. The growing adoption of decentralized and community-based clinical trial models is attracting investment, as sponsors seek to expand access, accelerate enrollment, and reach more representative patient populations. With big pharma continuing to ramp up research spending and with outsourcing penetration climbing across all trial phases, we expect deal activity in this sector to remain steady through the remainder of 2026.